300396.SZ
ST迪瑞
SZSE · Healthcare · C 制造业 · CN
CNY 7.14
−1.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 802.4M | 807.1M | 977.2M | 1.1B | 1.2B |
| Cost of Revenue | 473.8M | 479.6M | 472.4M | 545.0M | 585.7M |
| Gross Profit | 328.6M | 327.4M | 504.9M | 567.2M | 634.3M |
| Operating Expenses | |||||
| R&D Expense | 124.1M | 121.8M | 130.4M | 128.6M | 114.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 60.9M | 61.4M | 56.8M | 58.3M | 70.9M |
| Selling & Marketing Expense | 231.9M | 232.9M | 258.7M | 261.3M | 183.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 435.4M | 420.4M | 477.9M | 453.5M | 367.3M |
| Cost and Expenses | 909.2M | 900.0M | 950.3M | 998.5M | 953.0M |
| Operating Income (EBIT) | (313.6M) | (298.0M) | 66.9M | 160.0M | 292.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (314.2M) | (298.4M) | 68.9M | 159.3M | 291.4M |
| Income Tax Expense | (51.3M) | (52.4M) | 3.8M | 91.7K | 29.6M |
| Bottom Line | |||||
| Net Income | (262.8M) | (246.0M) | 65.2M | 159.2M | 261.8M |
| Earnings from Cont. Ops | (262.8M) | (246.0M) | 65.1M | 159.2M | 261.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (262.8M) | (246.0M) | 65.2M | 159.2M | 261.8M |
| Per Share | |||||
| Basic EPS | (CN¥0.96) | (CN¥0.90) | CN¥0.24 | CN¥0.59 | CN¥0.96 |
| Diluted EPS | (CN¥0.96) | (CN¥0.90) | CN¥0.24 | CN¥0.59 | CN¥0.95 |
| Revenue Per Share | CN¥2.96 | CN¥2.95 | CN¥3.60 | CN¥4.12 | CN¥4.47 |
| Shares | |||||
| Basic Shares Outstanding | 270.9M | 273.3M | 271.5M | 269.9M | 272.7M |
| Diluted Shares Outstanding | 270.9M | 273.3M | 271.5M | 269.9M | 272.7M |
| Profitability Metrics | |||||
| EBITDA | — | (248.3M) | 107.6M | 196.8M | 326.4M |
| D&A | — | 49.7M | 40.7M | 36.8M | 34.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026